CCO Oncology Podcast

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Episode Summary

Listen as experts discuss key clinical pearls and answer frequently asked questions on the use of CDK4/6 inhibitors for HR-positive/HER2-negative early and metastatic breast cancer in this podcast episode, including insights related to optimal sequencing and ensuring adherence to therapy.

Episode Notes

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include:

• Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. Gradishar
• Therapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. Abraham
• Addressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. Spring

Presenters:

Jame Abraham, MD, FACP
Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Laura Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Link to full program including downloadable slides and on-demand webcasts: 
https://bit.ly/4b5GFqq

To claim credit for listening to this episode, please visit the podcast online at the link above.